Experiment 1155963

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismEmpty organism
CitationGRIFFITH,JD: STARK,RJ: DING,JC: COOPER,IA:. (1986). VINCRISTINE NEUROTOXICITY ENHANCED IN COMBINATION CHEMOTHERAPY INCLUDING BOTH TENIPOSIDE AND VINCRISTINE.. 70(4)
Amount utilized
Compound isolated
DiseaseIN THIS PILOT STUDY NINE PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA WERE GIVEN COMBINATION CHEMOTHERAPY CONSISTING OF TENIPOSIDE(100G/SQ.M,DAYS 1-3), DOXORUBICIN(IV,30MG/SQ.M. DAYS 1-3), CYCLOPHOSPHAMIDE(300MG/SQ.M. IV,DAYS 1-3 AND DAYS 4-7), PREDNISOLONE(PO 100MG/SQ.M. DAYS 4-10), METHOTREXATE(100MG/SQ.M. IV DAY 8), LEUCOVORIN(30MG/SQ.M. IM 4 TIMES AT 6 HR INTERVALS AFTER METHOTREXATE), AND VINCRISTINE(1.4MG/SQ.M. IV DAYS 8, 15 AND 22 TO A MAXIMUM DOSE OF 2 MG). PERIPHERAL NEUROTOXICITY WAS SEVERE IN THESE CASES AND COULD BE DUE TO THE SEQUENTIAL USE OF VINCRISTINE AND TENIPOSIDE. CLINICAL SIGNS OF NEUROPATHY INCLUDED PARESTHESIA,DEEP TENDON REFLEXES ABSENT OR REDUCED IN THE ACHILLES TENDON,ARMS AND OR LEGS, BILATERAL FOOT DROP AND HAND WEAKNESS, AND REDUCED SENSATION IN THE FINGERS.
Dose amount1.4 MG
Number1
Qualitative resultEQUIVOCAL
AnimalHUMAN ADULT
Per unitSQ M BODY SURFACE
Dose expressionDOSE